Literature DB >> 25911587

Randomized controlled clinical trial evaluating multiplex polymerase chain reaction for pathogen identification and therapy adaptation in critical care patients with pulmonary or abdominal sepsis.

Sascha Tafelski1, Irit Nachtigall1, Thomas Adam2, Stefan Bereswill2, Jana Faust1, Andrey Tamarkin1, Tanja Trefzer1, Maria Deja1, Evgeny A Idelevich3, Klaus-Dieter Wernecke4, Karsten Becker3, Claudia Spies5.   

Abstract

OBJECTIVE: To determine whether a multiplex polymerase chain reaction (PCR)-based test could reduce the time required for initial pathogen identification in patients in an intensive care unit (ICU) setting.
METHODS: This double-blind, parallel-group randomized controlled trial** enrolled adults with suspected pulmonary or abdominal sepsis caused by an unknown pathogen. Both the intervention and control groups underwent the standard blood culture (BC) testing, but additional pathogen identification, based on the results of a LightCycler® SeptiFast PCR test, were provided in the intervention group.
RESULTS: The study enrolled 37 patients in the control group and 41 in the intervention group. Baseline clinical and demographic characteristics were similar in both groups. The PCR-based test identified a pathogen in 10 out of 41 (24.4%) patients in the intervention group, with a mean duration from sampling to providing the information to the ICU of 15.9 h. In the control group, BC results were available after a significantly longer period (38.1 h).
CONCLUSION: The LightCycler® SeptiFast PCR test demonstrated a significant reduction in the time required for initial pathogen identification, compared with standard BC.
© The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  LightCycler® SeptiFast; abdominal sepsis; blood culture; multiplex polymerase chain reaction; pneumonia; sepsis

Mesh:

Year:  2015        PMID: 25911587     DOI: 10.1177/0300060514561135

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

Review 1.  Beyond Blood Culture and Gram Stain Analysis: A Review of Molecular Techniques for the Early Detection of Bacteremia in Surgical Patients.

Authors:  Michelle H Scerbo; Heidi B Kaplan; Anahita Dua; Douglas B Litwin; Catherine G Ambrose; Laura J Moore; Col Clinton K Murray; Charles E Wade; John B Holcomb
Journal:  Surg Infect (Larchmt)       Date:  2016-02-26       Impact factor: 2.150

Review 2.  Emerging Technologies for Molecular Diagnosis of Sepsis.

Authors:  Mridu Sinha; Julietta Jupe; Hannah Mack; Todd P Coleman; Shelley M Lawrence; Stephanie I Fraley
Journal:  Clin Microbiol Rev       Date:  2018-02-28       Impact factor: 26.132

3.  Evaluation of the Septifast MGrade Test on Standard Care Wards--A Cohort Study.

Authors:  Franz Ratzinger; Irene Tsirkinidou; Helmuth Haslacher; Thomas Perkmann; Klaus G Schmetterer; Dieter Mitteregger; Athanasios Makristathis; Heinz Burgmann
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

4.  Implementation of short incubation MALDI-TOF MS identification from positive blood cultures in routine diagnostics and effects on empiric antimicrobial therapy.

Authors:  Robin Köck; Jörg Wüllenweber; Dagmar Horn; Christian Lanckohr; Karsten Becker; Evgeny A Idelevich
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-14       Impact factor: 4.887

5.  Probe-free label system for rapid detection of Cronobacter genus in powdered infant formula.

Authors:  Shiqian Fu; Yujun Jiang; Xia Jiang; Yueming Zhao; Sihan Chen; Xinyan Yang; Chaoxin Man
Journal:  AMB Express       Date:  2018-09-29       Impact factor: 3.298

6.  Mortality, intensive care treatment, and cost evaluation: Role of a polymerase chain reaction assay in patients with sepsis.

Authors:  Andrej Markota; Andreja Sinkovič
Journal:  J Int Med Res       Date:  2017-07-21       Impact factor: 1.671

7.  A prospective multicenter evaluation of direct molecular detection of blood stream infection from a clinical perspective.

Authors:  A E Nieman; P H M Savelkoul; A Beishuizen; B Henrich; B Lamik; C R MacKenzie; D Kindgen-Milles; A Helmers; C Diaz; S G Sakka; R P Schade
Journal:  BMC Infect Dis       Date:  2016-06-30       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.